Success Metrics

Clinical Success Rate

66.7%

Based on 4 completed trials

Completion Rate

67%(4/6)

Active Trials

2(22%)

Results Posted

75%(3 trials)

Terminated

2(22%)

Phase Distribution

Ph phase_2

33%

Ph phase_3

11%

Ph not_applicable

11%

Ph phase_1

44%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution9 total trials

Phase 1Safety & dosage

4(44.4%)

Phase 2Efficacy & side effects

3(33.3%)

Phase 3Large-scale testing

1(11.1%)

N/ANon-phased studies

1(11.1%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(4)

Terminated(2)

Other(1)

Detailed Status

Completed4

Terminated2

unknown1

Active, not recruiting1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 3

Trials by Phase

Phase 14 (44.4%)

Phase 23 (33.3%)

Phase 31 (11.1%)

N/A1 (11.1%)

Trials by Status

unknown111%

terminated222%

active_not_recruiting111%

recruiting111%

completed444%

Recent Activity

2 active trials

Showing 5 of 9

completedphase_2

DPX-Survivac and Checkpoint Inhibitor in DLBCL

NCT03349450

active_not_recruitingphase_1

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

NCT04895761

terminatedphase_1

Siplizumab for Sickle Cell Disease Transplant

NCT06078696

recruitingphase_3

Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients

NCT04314219

completednot_applicable

Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients

NCT02583828

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT03349450Phase 2

DPX-Survivac and Checkpoint Inhibitor in DLBCL

Completed

NCT04895761Phase 1

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Active Not Recruiting

NCT06078696Phase 1

Siplizumab for Sickle Cell Disease Transplant

Terminated

NCT04314219Phase 3

Comparing Post-Transplant Cyclophosphamide As GVHD Prophylaxis to Standard of Care for Acute Leukemia Patients

Recruiting

NCT02583828Not Applicable

Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients

Completed

NCT05243524Phase 2

Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Terminated

NCT04262427Phase 1

The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma

Unknown

NCT00326417Phase 1

Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301)

Completed

NCT03139851Phase 2

Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide

Completed

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9